glp-1/gip Science Behind GLP 1 GIP and Glucagon Receptor Agonists for Obesity Research | News & Announcements Science Behind GLP 1 GIP
Description
A dietitian breaks down the science behind the hype and how they really work.
Yale Medicine experts explain who qualifies, who can prescribe, and what to expect.
This article examines clinical safety data, GI mechanisms, and how genetic predispositions may influence medication tolerance in IBD patients see
It includes a clinically studied spore probiotic strain that works to maintain balance and comfort in your gut
Recent Findings Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D
